No Q2 Revenues for Compugen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its second quarter, down from $800,000 a year ago.

The company's revenues comprise mainly of research fees and milestone and do not include government grants, which Compugen records as a reduction of R&D costs.

For the three months ended June 30, net loss totaled $2.2 million, or $.06 per share, up 146 percent from a net loss of $896,000, or $.03 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.